We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Transcription Factor Deficit Spurs Tumor Development

By LabMedica International staff writers
Posted on 28 Jun 2017
Print article
Image: A photomicrograph of human breast cancer line MCF-7 cells (Photo courtesy of Wikimedia Commons).
Image: A photomicrograph of human breast cancer line MCF-7 cells (Photo courtesy of Wikimedia Commons).
A team of British cancer researchers found that the transcription factor proline-rich homeodomain protein (PRH/HHEX) played a tumor suppressive role in the breast, and they provided an explanation for the finding that low PRH mRNA levels were associated with a poor prognosis in breast cancer.

Breast tumors progress from hyperplasia to ductal carcinoma in situ (DCIS) and invasive breast carcinoma (IBC). In order to study the role of the PRH/HEX transcription factor in this progression, investigators at the University of Birmingham (United Kingdom) adapted a population of human breast cancer MCF-7 cells to under or over produce PRH/HEX.

They reported in the June 12, 2017, online edition of the journal Oncogenesis that transcriptionally inactive phosphorylated PRH was elevated in DCIS and IBC compared with tissues in the normal breast. To determine the consequences of PRH loss of function in breast cancer cells, they induced PRH depletion in their line of MCF-7 cells. They showed that PRH depletion resulted in increased MCF-7 cell proliferation in part at least due to increased vascular endothelial growth factor signaling. Moreover, they demonstrated that PRH depletion increased the formation of breast cancer cells with cancer stem cell-like properties.

In a mouse model, PRH overexpression inhibited the growth of mammary tumors. Taken together, these data indicated that PRH played a tumor suppressive role in the breast, and they provided an explanation for the finding that low PRH mRNA levels were associated with a poor prognosis in breast cancer.

Senior author Dr. Padma Sheela Jayaraman, senior lecturer in cancer biology at the University of Birmingham, said, "PRH is a protein that controls and regulates when genes are switched on or off. However, prior to our research, the role of this protein in breast cancer has been poorly understood. In the laboratory, we found that when PRH protein levels are reduced in a breast tumor the cells are more able to divide, speeding up the progression of the tumor. Moreover, we identified some of the genes which are regulated by PRH and specifically contribute to the increased cell division."

"We made the significant finding that high levels of PRH actually blocked the formation of the tumors, therefore our data suggests that PRH can block tumor formation in some breast cancers," said Dr. Jayaraman. "We propose that monitoring PRH protein levels or activity in patients with breast cancer could be particularly important for assessing their prognosis. In addition, since PRH is known to be important in multiple cell types, this work has important implications for other types of cancer."

Related Links:
University of Birmingham

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.